2023 - Research.com Medicine in United Kingdom Leader Award
2022 - Research.com Best Scientist Award
Internal medicine, Surgery, Gastroenterology, Chemotherapy and Colorectal cancer are his primary areas of study. The study of Internal medicine is intertwined with the study of Oncology in a number of ways. He interconnects Clinical trial and Capecitabine in the investigation of issues within Surgery.
His studies deal with areas such as Phases of clinical research, Survival rate, Regimen, Neutropenia and Performance status as well as Gastroenterology. His Chemotherapy research is multidisciplinary, incorporating perspectives in Toxicity, Clinical endpoint, Pancreatic cancer and Prospective cohort study. As a part of the same scientific family, he mostly works in the field of Colorectal cancer, focusing on Chemoradiotherapy and, on occasion, Total mesorectal excision.
David Cunningham mainly investigates Internal medicine, Oncology, Surgery, Chemotherapy and Colorectal cancer. His Gastroenterology research extends to the thematically linked field of Internal medicine. His study looks at the relationship between Oncology and topics such as Gemcitabine, which overlap with Pancreatic cancer.
His research links Hazard ratio with Surgery. His work deals with themes such as Carcinoma, Disease, Toxicity, Lymphoma and Adenocarcinoma, which intersect with Chemotherapy. His studies in Colorectal cancer integrate themes in fields like Cancer research and Chemoradiotherapy, Radiation therapy.
His primary scientific interests are in Internal medicine, Oncology, Colorectal cancer, Chemotherapy and Cancer research. His work in Internal medicine is not limited to one particular discipline; it also encompasses Gastroenterology. His Gastroenterology study incorporates themes from Survival rate, Gemcitabine, Fluorouracil and Performance status.
His work carried out in the field of Oncology brings together such families of science as Phases of clinical research, Randomized controlled trial, Rituximab, Biomarker and Nivolumab. In his study, Capecitabine is inextricably linked to Surgery, which falls within the broad field of Colorectal cancer. His Chemotherapy study also includes
David Cunningham focuses on Internal medicine, Oncology, Colorectal cancer, Surgery and Gastroenterology. Internal medicine is represented through his Hazard ratio, Chemotherapy, Survival rate, Clinical trial and Randomized controlled trial research. David Cunningham combines subjects such as Biomarker, Cancer, Fluorouracil and Precision medicine with his study of Oncology.
David Cunningham works mostly in the field of Colorectal cancer, limiting it down to topics relating to Immunohistochemistry and, in certain cases, Prospective cohort study. In his study, Clinical endpoint and Liver function is strongly linked to Capecitabine, which falls under the umbrella field of Surgery. His study in Gastroenterology is interdisciplinary in nature, drawing from both Phases of clinical research, Carcinoma, Gemcitabine, Survival analysis and Performance status.
This overview was generated by a machine learning system which analysed the scientist’s body of work. If you have any feedback, you can contact us here.
Perioperative Chemotherapy versus Surgery Alone for Resectable Gastroesophageal Cancer
David Cunningham;William H. Allum;Sally P. Stenning;Jeremy N. Thompson.
The New England Journal of Medicine (2006)
Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer.
David Cunningham;Yves Humblet;Salvatore Siena;David Khayat.
The New England Journal of Medicine (2004)
Irinotecan combined with fluorouracil compared with fluorouracil alone as first-line treatment for metastatic colorectal cancer: a multicentre randomised trial
J Y Douillard;D Cunningham;Arnaud Roth;M Navarro.
The Lancet (2000)
Cisplatin plus Gemcitabine versus Gemcitabine for Biliary Tract Cancer
Juan Ignacio Valle;Harpreet Singh Wasan;Daniel H Palmer;David Cunningham.
The New England Journal of Medicine (2010)
Capecitabine and oxaliplatin for advanced esophagogastric cancer.
David Cunningham;Alicia F C Okines;Sue Ashley.
The New England Journal of Medicine (2008)
Panitumumab-FOLFOX4 treatment and RAS mutations in colorectal cancer
Jean Yves Douillard;Kelly S. Oliner;Salvatore Siena;Josep Tabernero.
The New England Journal of Medicine (2013)
Ramucirumab plus paclitaxel versus placebo plus paclitaxel in patients with previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma (RAINBOW): a double-blind, randomised phase 3 trial
Hansjochen Wilke;Kei Muro;Eric Van Cutsem;Sang Cheul Oh.
Lancet Oncology (2014)
Comparison of adjuvant gemcitabine and capecitabine with gemcitabine monotherapy in patients with resected pancreatic cancer (ESPAC-4): a multicentre, open-label, randomised, phase 3 trial
John P. Neoptolemos;John P. Neoptolemos;Daniel H. Palmer;Daniel H. Palmer;Paula Ghaneh;Eftychia E. Psarelli.
The Lancet (2017)
The role of probiotics in aquaculture
José Luis Balcázar;Ignacio de Blas;Imanol Ruiz-Zarzuela;David Cunningham.
Veterinary Microbiology (2006)
Randomised trial of irinotecan plus supportive care versus supportive care alone after fluorouracil failure for patients with metastatic colorectal cancer
David Cunningham;Seppo Pyrhönen;Roger D James;Cornelis J A Punt.
The Lancet (1998)
If you think any of the details on this page are incorrect, let us know.
We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below: